

## Crystal Structures of Large-Volume commercial Pharmaceuticals

James A Kaduk<sup>1</sup>, Tawnee M Ens<sup>1</sup>, Nicolas C Boaz<sup>1</sup>, Anja Viera Dosen<sup>2</sup>, Thomas N Blanton<sup>2</sup>  
<sup>1</sup>North Central College, <sup>2</sup>ICDD

[kaduk@polycrystallography.com](mailto:kaduk@polycrystallography.com)

As part of a continuing project, the room-temperature crystal structures of eight commercial pharmaceutical APIs have been solved and refined using synchrotron X-ray powder diffraction data (11-BM at APS) and optimized using density functional techniques. Danofloxacin mesylate (C<sub>19</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>3</sub>) (CH<sub>3</sub>O<sub>3</sub>S) crystallizes in space group P1 with  $a = 6.77467$ ,  $b = 12.4975$ ,  $c = 12.8277$  Å,  $\alpha = 84.8277^\circ$ ,  $\beta = 87.7524^\circ$ ,  $\gamma = 74.9923^\circ$ ,  $V = 1044.67$  Å<sup>3</sup>, and  $Z = 2$ . Meglumine diatrizoate (C<sub>7</sub>H<sub>17</sub>NO<sub>5</sub>) (C<sub>11</sub>H<sub>8</sub>I<sub>3</sub>N<sub>2</sub>O<sub>4</sub>) crystallizes in space group P2<sub>1</sub> (#4) with  $a = 10.74697(4)$ ,  $b = 6.49364(2)$ ,  $c = 18.52774(7)$  Å,  $\beta = 90.2263(3)$ ,  $V = 1292.985(5)$  Å<sup>3</sup>, and  $Z = 2$ . Encorafenib C<sub>22</sub>H<sub>27</sub>ClFN<sub>7</sub>O<sub>4</sub>S crystallizes in space group P2<sub>1</sub> (#4) with  $a = 16.17355(25)$ ,  $b = 9.52338(11)$ ,  $c = 17.12368(19)$  Å,  $\beta = 89.9928(22)$ ,  $V = 2637.49(4)$  Å<sup>3</sup>, and  $Z = 4$ . Omadacycline dihydrate C<sub>29</sub>H<sub>40</sub>N<sub>4</sub>O<sub>7</sub>(H<sub>2</sub>O)<sub>2</sub> crystallizes in space group R3 (#146) with  $a = 24.34435(8)$ ,  $c = 14.55213(5)$  Å,  $V = 7468.849(29)$  Å<sup>3</sup>, and  $Z = 9$ . Nicarbazin (C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>5</sub>) (C<sub>6</sub>H<sub>8</sub>N<sub>2</sub>O) crystallizes in space group P-1 (#2) with  $a = 6.90659(8)$ ,  $b = 12.0794(4)$ ,  $c = 13.5040(7)$  Å,  $\alpha = 115.5709(11)$ ,  $\beta = 102.3658(6)$ ,  $\gamma = 91.9270(4)^\circ$ ,  $V = 982.466(5)$  Å<sup>3</sup>, and  $Z = 2$ . Oxfendazole C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>S crystallizes in space group P2<sub>1</sub>/c (#14) with  $a = 18.87326(26)$ ,  $b = 10.40333(5)$ ,  $c = 7.25089(5)$  Å,  $\beta = 91.4688(10)^\circ$ ,  $V = 1423.206(10)$  Å<sup>3</sup>, and  $Z = 4$ . Butenafine hydrochloride C<sub>23</sub>H<sub>28</sub>NCl crystallizes in space group P2<sub>1</sub> (#4) with  $a = 13.94807(5)$ ,  $b = 9.10722(2)$ ,  $c = 16.46676(6)$  Å,  $\beta = 93.9663(5)^\circ$ ,  $V = 2086.733(8)$  Å<sup>3</sup>, and  $Z = 4$ . Besifloxacin hydrochloride C<sub>19</sub>H<sub>22</sub>ClFN<sub>3</sub>O<sub>3</sub>Cl crystallizes in space group P1 (#1) with  $a = 5.36596(8)$ ,  $b = 10.3234(4)$ ,  $c = 17.9673(14)$  Å,  $\alpha = 98.122(5)$ ,  $\beta = 92.9395(9)$ ,  $\gamma = 96.1135(3)^\circ$ ,  $V = 977.483(13)$  Å<sup>3</sup>, and  $Z = 2$ . All of structure solutions presented “interesting” features. Other new structures may be presented as they become available.